Literature DB >> 2179469

An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings.

G Agius1, G Dindinaud, R J Biggar, R Peyre, V Vaillant, S Ranger, J Y Poupet, M F Cisse, M Castets.   

Abstract

In 1984-1985, an outbreak of respiratory syncytial virus (RSV) infection occurred in two geriatric wards. Among 68 patients (mean age +/- SD = 82.5 +/- 12.5 with respiratory signs, 52 had signs caused by RSV infection. Among all patients, the clinical and serological attack rates were 61.2% and 75.0%, respectively. The most frequent clinical presentation was intensive coughing (96.1%) and fever (96.1%) associated with expectorate (63.5%). The duration of the respiratory symptoms was 5 to 7 days. The disease gradually resolved, although in eight (15.4%) patients complications occurred. For periods of up to 1 year after infection, 172 sera were obtained and tested by complement fixation test (CFT), fluorescent assays for titrating specific IgG, IgA, and IgM, and Western blotting. Specific IgM appeared in six (11.5%) of the infected patients and peaked 2 to 6 months after infection, and there was no significant correlation with severity of clinical symptoms. However, higher peak G and A antibody responses were observed in persons with rales (CFT: P = 0.008; IgG: P = 0.042; IgA: P = 0.020), cough (IgG: P = 0.034), sputum (IgG: P = 0.030), dyspnea (CFT: P = 0.024), conjunctivitis (CFT: P = 0.025), and bronchitis (CFT: P = 0.018). The temporal patterns of IgA and CFT results were found to be similar, whereas IgG peaked later, i.e., between 2 and 6 months. The patients with the most severe symptoms had the highest antibody titers obtained by conventional tests and by Western blots. Thus, RSV can be an epidemic pathogen among elderly persons, although this illness is usually mild.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2179469     DOI: 10.1002/jmv.1890300208

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  35 in total

Review 1.  Laboratory diagnosis of lower respiratory tract infections: controversy and conundrums.

Authors:  Karen C Carroll
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

2.  Baculovirus expression of the respiratory syncytial virus fusion protein using Trichoplusia ni insect cells.

Authors:  M Parrington; S Cockle; P Wyde; R P Du; E Snell; W Y Yan; Q Wang; L Gisonni; S Sanhueza; M Ewasyshyn; M Klein
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

Review 3.  Intranasal antibody prophylaxis for protection against viral disease.

Authors:  R Weltzin; T P Monath
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

4.  Respiratory syncytial virus infection in older adults: an under-recognized problem.

Authors:  Angela R Branche; Ann R Falsey
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

5. 

Authors:  François Freymuth; Geneviève Eugène; Jacques Brouard; Astrid Vabret; Joëlle Petitjean; Françoise Bonnin
Journal:  Ann Inst Pasteur Actual       Date:  2000-04-05

Review 6.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

7.  Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.

Authors:  Elaine M Castilow; Steven M Varga
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

Review 8.  Ocular tropism of respiratory viruses.

Authors:  Jessica A Belser; Paul A Rota; Terrence M Tumpey
Journal:  Microbiol Mol Biol Rev       Date:  2013-03       Impact factor: 11.056

9.  Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants.

Authors:  C Osiowy; D Horne; R Anderson
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

10.  The prediction of epidemics of respiratory infection.

Authors:  D M Fleming
Journal:  Eur J Epidemiol       Date:  1994-08       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.